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Background/Aims
Reliable diagnostic instruments for measuring the presence of functional gastrointestinal disorders based on the Rome III criteria 
have been lacking in Japan. The aims of the present study were to translate and validate the Rome III diagnostic questionnaire 
which was widely used in Western countries.
Methods
The original version of Rome III diagnostic questionnaire was translated from English into Japanese through 3 independent for-
ward translations, resolution, back translation and reconciliation of the differences. Forty-nine patients with irritable bowel syn-
drome (IBS), 32 patients with functional dyspepsia (FD) and 56 subjects without any current GI symptoms as controls were re-
cruited from three hospitals located in different regions of Japan and completed the IBS and FD diagnostic modules twice with-
in 14 days. Kappa statistic was used to assess test-retest reliability. The sensitivity and specificity of each diagnostic module for 
distinguishing IBS or FD patients from controls was tested.
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Results
Median kappa statistics were 0.63 for the translated IBS diagnostic module and 0.68 for the FD module. The sensitivity, specif-
icity, and positive predict value of the IBS module against physician diagnosis was 61.2%, 100%, and 100% and those of the 
FD module was 53.2%, 98.2%, and 94.4%, respectively. Meanwhile, IBS patients were significantly more likely to report blood 
in stools compared to controls (18.4% vs 1.8%, P ＜ 0.01).
Conclusions
The IBS and FD diagnostic modules on the Japanese version of the Rome III diagnostic questionnaire are valid and reliable. 
Further studies are warranted to elucidate the diagnostic utility of the red flag questionnaire.
(J Neurogastroenterol Motil 2015;21:537-544)
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Introduction
Rome III diagnostic criteria based on subjective gastro-
intestinal (GI) complaints are the most widely used criteria to di-
agnose functional gastrointestinal disorders (FGIDs).1 Irritable 
bowel syndrome (IBS) and functional dyspepsia (FD) are the 
most common FGIDs both in the Western and the Eastern 
countries.2,3 The Rome committee critically considered the avail-
able evidence, and multinational expert opinion, when they re-
vised the former Rome II diagnostic criteria4 and updated diag-
nosis and treatment recommendations.
The Rome III diagnostic criteria for FGIDs provide a 
framework for symptom-based diagnosis. The Rome committee 
proposed that subtyping of IBS should be based on frequency 
and consistency of stools,5 which can be assessed with the aid of 
the Bristol Stool Form Scale.6 The committee also proposed that 
the newly defined entities of (1) meal-induced dyspeptic symp-
toms (postprandial distress syndrome, PDS), and (2) epigastric 
pain (epigastric pain syndrome, EPS) should be treated as sub-
groups of FD for pathophysiological and therapeutic research 
purposes.3
The Rome Foundation developed a questionnaire for the 
Rome III diagnostic criteria for FGIDs. They also validated the 
questionnaire to assess the test-retest reliability of the ques-
tionnaire for all diagnoses combined and for individual questions, 
and to test the sensitivity and specificity of the questionnaire for 
identifying medically diagnosed patients with FGIDs. The Rome 
III diagnostic questionnaire for IBS contains 10 items and the 
one for FD contains 18 items; answers to questions are on an or-
dinal scale with individual frequency thresholds for each 
question.7 While “red flag” questions are not part of the diag-
nostic questionnaire, these features, if present, should prompt the 
clinician to consider further investigations to exclude other seri-
ous medical conditions. Briefly, the “red flag” questions include 
history for the past 3 months of fever, weight loss, cancer in fam-
ily members, blood mixed with stool, anemia and change in bowel 
habit after age 50.8 Red flags may be useful for identifying pa-
tients who require additional diagnostic evaluation in the clinical 
settings. However, it has been investigated that incorporating 
them into the Rome II criteria did not improve sensitivity and re-
sulted in too many missed diagnoses of IBS.8
Previously, we have developed and validated the Japanese 
translated version of the Rome II modular questionnaire based 
on the former diagnostic criteria for IBS.9 There are a few studies 
to investigate prevalence of FGIDs using the Rome III criteria in 
Japan.10,11 However, reliable diagnostic instruments for measur-
ing the presence of FGIDs based on the Rome III criteria, com-
parable to those used in Western countries, have been lacking in 
Japan. To make cross-cultural comparisons possible, it is indis-
pensable to develop common diagnostic measures for FGIDs.12 
The aims of the present study were to translate the Rome III di-
agnostic questionnaire into Japanese and to validate them in 
Japanese patients with IBS and FD. In addition, we investigated 
whether the utility of red flag symptoms that can be incorporated 
into the Japanese instruments.
Materials and Methods
Translation
The Rome III diagnostic questionnaire was developed as a 
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diagnostic instrument for functional GI disorders according to 
the Rome III diagnostic criteria.7 All answers in the Rome III di-
agnostic questionnaire were in ordinal scale with individual fre-
quency thresholds except for 22 of 81 items which had a “yes” or 
“no” response. A score was given to each of the responses for or-
dinal scaled items (0, never; 1, sometimes; 2, often; 3, most of the 
time; and 4, always). There were 10 items for IBS diagnosis, 18 
items for FD diagnosis, and 6 items for the “red flag” symp-
toms/conditions (blood in stools, unintended weight loss of over 
10 pounds (4.5 kg), fever, symptom onset after age 50, and fam-
ily histories of any GI cancer and inflammatory bowel disease) 
were used.
A group of the Japanese co-investigators (S.F. and M.K.) in-
dependently translated the English version of the Rome III diag-
nostic questionnaire into the Japanese language. Meanwhile, an 
investigator (S.N.) independently translated it in the same way to 
resolve the potential incongruity of the linguistic expressions be-
tween the Eastern and Western areas in Japan. After the descrip-
tions of each item had been discussed with specialists, the 
Japanese version of the instruments was then counter-translated 
into English by a native speaker of English. This back-translated 
version was sent to the Rome Committee, compared with the orig-
inal versions, and discussed to confirm that the Japanese-trans-
lated versions were comparable to the English versions of the 
Rome III diagnostic questionnaire. Then, the Japanese version of 
the instruments was approved by the authors of the original 
English versions. 
Subjects
Forty-nine consecutive patients (21 females, mean age 40.9 
years) clinically diagnosed by physicians as having IBS according 
to Rome III diagnostic criteria, and 32 patients with FD (26 fe-
males, mean age 53.8 years) diagnosed according to Rome III 
were enrolled from GI clinics in Tohoku University Hospital, 
Hyogo College of Medicine Hospital, and Japan Community 
Health care Organization Shiga Hospital, Japan. Clinical exami-
nations including upper and/or lower GI endoscopy had been 
carefully performed and no abnormal findings to explain GI 
symptoms had been detected when diagnosed as FD or IBS. 
Fifty-six subjects (32 females, mean age 51.4 years) who visited 
at the same hospitals for an annual health check (n = 31) or treat-
ment of mild hypertension/hyperlipidemia (n = 25) but did not 
have any current GI complaints and any past history of abdomi-
nal surgeries except for appendectomy were also recruited as 
controls. Control subjects were carefully diagnosed as not having 
any FGID by their physicians.
All the participants were Japanese and were 18 years of age or 
older. They did not have any organic GI diseases or any other se-
vere physical or psychiatric complications. Informed consent was 
obtained from all the subjects. However, a study ID was assigned 
to insure that the investigators could not identify any subjects. 
This study was approved by the Ethics Committees of Tohoku 
University Graduate School of Medicine, Hyogo College of 
Medicine and Japan Community Health care Organization 
Shiga Hospital. 
Severity of Irritable Bowel Syndrome 
Symptoms
The IBS symptom severity scale (IBS-SSS) was developed 
and is widely used in Western countries to assess the severity of 
lower GI symptoms and the degree to which the quality of life is 
impaired by IBS.12 This instrument has five items, and the total 
score can range from 0 to 500. The IBS-SSS scores severity and 
frequency of abdominal pain, severity of abdominal distension, 
dissatisfaction of bowel movements, and the interference with life, 
with a 100-point scale (0, none and 100, worst) for each question. 
With the possible exception of the bowel dissatisfaction item, 
these symptom questions are appropriate for characterizing the 
severity of symptoms in FD as well as the severity of IBS. In the 
original English version, IBS is graded as mild (75-174), moder-
ate (175-299), or severe (300-500) on the basis of clinical ob-
servations of IBS patients.13 Our group previously developed the 
Japanese version of IBS-SSS and has confirmed the reliability 
and validity of this questionnaire.9
Procedure
Physician diagnosis for IBS, FD, and control was coded into 
numbers. The diagnostic code and a study ID were written on a 
cover page of the first questionnaire for each subject in advance. 
The first questionnaire containing all 81 questions on the original 
complete version plus the IBS-SSS was completed by each partic-
ipant during a clinic visit. Fourteen days later, all subjects were 
asked to complete a second questionnaire and return it by post to 
test for reproducibility of answers. The follow-up questionnaire 
included only the modules for diagnoses of IBS (10 items, the 
IBS diagnostic module) and FD (18 items, the FD diagnostic 
module). 
Statistical Methods
The test-retest reliability of the questionnaire was judged 
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Table 1. Characteristics of Samples
Controls FD IBS
Number (females) 56 (32) 32 (26) 49 (21)
Age (yr) 51.4 ± 2.2 53.8 ± 3.0   40.9 ± 2.3a,c
Number of subtypes of IBS
    Diarrhea - - 28
    Constipation - -   9
    Mixed - - 11
    Unclassified - -   1
Number of subtypes of FD
    PDS - 25 -
    EPS -   7 -
Number of types of non-GI controls
    Annual health check 31 - -
    Mild hypertension/hyperlipidemia 25 - -
IBS-SSS total score 30 ± 7 192 ± 16a   252 ± 16a,c
    Abdominal pain severity 1 ± 1 21 ± 4a   45 ± 4a,c
    Abdominal pain frequency 0.1 ± 0.0   2.7 ± 0.6a     4.3 ± 0.5a,b
    Abdominal bloating 2 ± 1 42 ± 6a 38 ± 5a
    Bowel dissatisfaction 18 ± 4 55 ± 6a 65 ± 4a
    Interference with life 8 ± 3 46 ± 6a 62 ± 4a
Characteristics of each group were shown.
FD, functional dyspepsia; IBS, irritable bowel syndrome; PDS, postprandial distress syndrome; EPS, epigastric pain syndrome; GI, gastrointestinal; IBS-SSS, IBS 
symptom severity scale. 
Data were expressed as mean ± SEM, aP ＜ 0.01 vs Controls; bP ＜ 0.05, cP ＜ 0.01 vs FD.
with the use of the Kappa statistic to assess concordance between 
questionnaire responses on two separate occasions. The Pearson's 
chi-square tests were used to assess the agreement between a pos-
itive diagnosis by the Japanese version of Rome III diagnostic 
questionnaire and a clinical diagnosis assessed by their 
physicians. The sensitivity, specificity, and positive predictive 
value of the diagnostic questionnaire for discriminating IBS pa-
tients from controls, and for discriminating FD patients from 
controls were also analyzed. One-way analysis of variance 
(one-way ANOVA) was used to assess difference in the symptom 
severity scores between the clinical diagnostic groups. The dis-
criminant validity was measured by comparing the grade of se-
verity based on the IBS-SSS between subjects with Rome-pos-
itive and Rome-negative IBS using the nonparametric correlation 
coefficient, Kendall's tau-b. The proportion of each red flag 
symptom/condition was compared using the Fisher’s exact test 
between the clinical diagnostic groups.
Results
No apparent modifications were required to resolve incon-
sistencies between the forward translations into the Japanese 
language. The translation prepared by S.F. and M.K. was pri-
marily selected as the final version at this stage. When comparing 
the back translation to the original English version minor adjust-
ments in the choice of words for “bothersome” (questions 26 and 
39), “retching” (question 36), and “several” (question 79) were 
made in the Japanese translation. The Rome foundation board ap-
proved the completed translation in January 2010 (Supplementary 
Figure). 
Characteristics of the sample are shown in Table 1. There 
was no difference in gender ratio among the groups. Patients with 
IBS were significantly younger in age compared with FD pa-
tients or control subjects. Each patient with IBS was subtyped as 
IBS with diarrhea (n = 28), IBS with constipation (n = 9), 
mixed IBS (n = 11), or unclassified IBS (n = 1) by their physi-
cian according to dominant stool consistencies. Each patient with 
FD was subtyped as postprandial distress syndrome (PDS, n = 
25) or epigastric pain syndrome (EPS, n = 7) by their physician 
based on the upper GI symptoms. None of FD patients was diag-
nosed as overlap of PDS and EPS.
The total score on the IBS-SSS in patients with IBS was sig-
nificantly higher than FD patients or control subjects (P ＜ 0.01, 
respectively; Table 1). IBS patients also showed significantly 
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Table 4. Discriminative Validity With the Irritable Bowel Syndrome- 
Symptom Severity Scale in the Rome III Diagnostic Questionnaire 
(Adapted from Francis et al13)
IBS-SSS Score 0-74 75-174 175-299 300-500 Total
 Rome IBS (+)   0   7 15 11   33
 Rome IBS (–) 49 22 20   9 100
 Total 49 29 35 20 133
Score on the irritable bowel syndrome-symptom severity scale (IBS-SSS) was 
graded as mild (75-174), moderate (175-299), or severe (300-500). Subjects 
with Rome-positive IBS had more severe symptoms compared to those who 
were not diagnosed as IBS (P ＜ 0.001). 
Data were expressed as number.








Blood in stools   1.8 12.5  18.4b
Unintended weight loss 0  12.5a  10.2a
Fever 0 0   6.0
Bowel symptom onset after age 50 10.8 30.0  40.0a
Family history of any GI cancer 28.6 28.1 25.5
Family history of IBD 0   3.4   4.2
Frequencies of the self-reported symptoms or family histories which would 
suggest further evaluation to exclude organic gastrointestinal (GI) diseases were 
shown. 
FD, functional dyspepsia; IBS, irritable bowel syndrome; IBD, inflammatory 
bowel disease. 
aP ＜ 0.05, bP ＜ 0.01 vs Controls (Fisher’s exact test).
Table 2. Agreement Between Physician Diagnosis and the Irritable 
Bowel Syndrome Diagnostic Module
 Diagnosis IBS Controls Total
 Rome IBS (+) 30   0   30
 Rome IBS (–) 19 56   75
 Total 49 56 105
Sensitivity of the irritable bowel syndrome (IBS) diagnostic module was 61.2%, 
specificity (100%), and positive predict value (100%). 
Data were expressed as number.
Table 3. Agreement Between Physician Diagnosis and the Functional 
Dyspepsia Diagnostic Module
 Diagnosis FD Controls Total
 Rome FD (+) 17   1 18
 Rome FD (–) 15 55 70
 Total 32 56 88
Sensitivity of the functional dyspepsia (FD) diagnostic module was 53.2%, 
specificity (98.2%), and positive predict value (94.4%). 
Data were expressed as number.
higher scores than FD patients on IBS-SSS items measuring the 
intensity and frequency of abdominal pain (Table 1). However, 
there was no difference in the scores for abdominal bloating, bow-
el dissatisfaction or interference with life on the IBS-SSS between 
IBS and FD groups. Control subjects had significantly lower 
symptom scores for all subscales and the overall symptom severity 
score on the IBS-SSS compared with IBS or FD patients (P ＜ 
0.01, respectively; Table 1).
With respect to the test-retest reliability for the Rome III di-
agnostic questionnaire, median kappa statistic for the IBS diag-
nostic module was 0.63. Median kappa statistic for the FD mod-
ule was 0.68. 
The instrument for the symptom-based IBS diagnostic ques-
tionnaire was in modest agreement with physician diagnosis; sen-
sitivity of 61.2% and specificity of 100% for distinguishing IBS 
from health (Table 2). The positive predictive value (PPV) on 
the IBS module was 100%. When applied the functional bowel 
disorders (FBD) module on the Rome III criteria1 instead of the 
IBS module, the sensitivity and specificity were 91.8% and 
50.0%. PPV on the FBD module was 61.6%. 
The FD module was also in modest agreement with physi-
cian diagnosis; sensitivity of 53.2%, specificity of 98.2% and PPV 
of 94.4% for distinguishing FD from health (Table 3). None of 
subjects with hypertension or hyperlipidemia (n = 25) was iden-
tified as IBS or FD. It is interesting to note that 19 of 49 (39%) 
patients with IBS were also diagnosed as FD when using the 
Rome III diagnostic questionnaire. On the other hand, 3 of 32 
(9%) patients with FD were overlapping IBS.
When the score on the IBS-SSS for all the participants was 
graded as mild graded as mild (75-174), moderate (175-299), or 
severe (300-500),13 subjects with Rome-positive IBS (n = 33) 
significantly had more severe symptoms compared to those who 
were not diagnosed as IBS (Rome-negative IBS, n = 100) using 
the diagnostic questionnaire (Kendall’s tau-b = 0.45, P ＜ 
0.001; Table 4).
With respect to frequencies of the red flags, IBS patients 
were significantly more likely to report blood in stools (18.4% vs 
1.8%, P ＜ 0.01; Fisher’s exact test) (Table 5), unintended 
weight loss (10.2% vs 0%, P ＜ 0.05) and new bowel symptom 
onset after age 50 (40.0% vs 10.8%, P ＜ 0.05) compared to 
controls. FD patients were more likely to report only unintended 
weight loss (12.5% vs 0%, P ＜ 0.05) compared to controls. 
There was no significant difference in frequency of fever or fam-
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ily history of any GI cancer or inflammatory bowel disease be-
tween the groups.
Discussion
The Rome III diagnostic questionnaire was translated into 
Japanese using the guidelines recommended by the Rome 
Foundation, and the translated instrument was reviewed and ap-
proved by the Rome Foundation. In this study we evaluated the 
validity of the Japanese-translated Rome III diagnostic ques-
tionnaire by examining the concordance between questionnaire 
based diagnoses and clinical diagnoses in patients with IBS and 
FD attending gastroenterology out-patient clinics in Japan. We 
found modest sensitivity for both the IBS questionnaire module 
(61.2%) and the FD module (53.2%). However, the specificity 
(100% for IBS, 98.2% for FD) and the PPV (100% for IBS and 
94.4% for FD) were excellent. This suggests that clinician-diag-
nosed FD may be missed by the Japanese Rome III diagnostic 
questionnaire, but few subjects without FD will be incorrectly 
classified as IBS or FD cases.
We compared the sensitivity and specificity of the Japanese 
Rome III Diagnostic Questionnaire to the sensitivity and specific-
ity of the Rome III Diagnostic Questionnaire in other languages. 
The original English language version of the questionnaire was 
tested in 328 patients with IBS diagnosed by gastroenterologists 
and 554 healthy controls, and sensitivity-defined as the pro-
portion of medically diagnosed IBS patients identified by the 
questionnaire-was 71%, while specificity-defined as the pro-
portion of healthy controls correctly classified as non-IBS-was 
88%.14 A translation of the Rome III questionnaire into the 
Malaysian language similarly showed a sensitivity of 81% and 
specificity of 100% for discriminating 31 clinically diagnosed 
IBS patients from 31 healthy controls.15 A translation of the 
Rome III questionnaire into Portuguese discriminated medically 
diagnosed patients with FD from health controls with a sensi-
tivity of 91% and specificity of 95%.16 It has been reported that a 
sensitivity of the modified Rome III Diagnostic Questionnaire 
differs among the Asian countries,17 suggesting that socio-cul-
tural perspective and/or the linguistic nuances might be taken in-
to account to translate the original questionnaire into different 
languages.
In studies which have tested the ability of the Rome III ques-
tionnaire to discriminate medically diagnosed IBS patients from 
patients with other gastrointestinal diagnoses such as inflamma-
tory bowel disease or FD rather than discriminating them from 
healthy controls, performance has been more modest: In one 
study using the Rome II criteria, the questionnaire’s sensi-
tivity-defined as the ability to discriminate IBS patients from 
those with other gastrointestinal diagnoses-was 60% and specific-
ity was 56%.18 In a Norwegian study, which tested the discrim-
ination of IBS from patients with other causes of abdominal pain, 
sensitivity was 39% and specificity was 63%.19 On the other hand, 
using with the Korean version of the Rome III questionnaire, the 
sensitivity was 77.8% for the IBS module and 70.0% for the FD 
module and specificity was 81.6% and 63.0% when discriminated 
clinical IBS or FD patients from subjects who visited at gastro-
enterologists for any other reasons.20 These data show that the 
sensitivity and specificity of the Japanese Rome III Diagnostic 
Questionnaire is as good as the English original and other trans-
lations of the Rome III questionnaire when similar method-
ologies are used to evaluate sensitivity and specificity. In this 
study, test-retest reliability over an interval of two weeks was ac-
ceptable with median kappa of 0.63 for IBS and 0.68 for FD. 
However, this is somewhat below the test-retest coefficient of 82% 
found for the English language version of the questionnaire.14 
In the present study, frequencies of reporting “red flag” 
symptoms (eg, blood in stools and unintended weight loss) were 
concordant with previous reports.8,21 It is not surprising that the 
frequency of family history of any GI cancer in our findings was 
relatively high in each group (25.5 to 28.6%, Table 5) since gas-
tric and colon cancers are very common in the Japanese 
population.22 Notably, the red flags are not automatically cause 
for alarm signs. A separate, benign problem (eg, rectal bleeding 
caused by hemorrhoids) is often found that explains them. In the 
present study, no organic abnormality had been detected in the 
colon for all of patients who were diagnosed as IBS with colono-
scopy or barium enema despite the self-reported alarm symptoms 
on the red flag questionnaire. Whitehead et al8 reported that pa-
tients with IBS or other functional bowel disorders are highly 
likely to report red flag symptoms, suggesting that these symp-
toms should not be incorporated into the symptom-based Rome 
criteria as exclusions. Therefore, the “red flag” questionnaires are 
not meant to be used for the discrimination of patients with 
FGIDs from patients who have any serious conditions but are 
used for identifying patients who may require further diagnostic 
testing to determine whether organic diseases are present. 
A limitation of this and all other studies seeking to validate 
symptom based diagnostic criteria for FGIDs is that there is no 
biomarker to serve as a gold standard. The approach taken here 
of comparing questionnaire based diagnoses to medical diagnoses 
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made by experienced clinicians has been employed in other stud-
ies, but it should be acknowledged that clinicians often disagree 
about the diagnosis of an FGID in a specific patient.14 A second 
study limitation was that estimates of sensitivity and specificity 
were based on the ability of the Rome III Diagnostic Question-
naire to discriminate healthy controls from patients with FGIDs. 
This over-estimates the ability to discriminate patients with 
FGIDs from patients with other gastrointestinal symptoms, 
which is more important to clinicians than the ability to dis-
tinguish patients with FGIDs from healthy controls. Moreover, 
it is also important to evaluate whether the questionnaire could 
differentiate different types of FGIDs. Thirdly, we did not inves-
tigate whether participants may take any medication for GI 
and/or the other reasons. It is unlikely that participants selected 
by physicians may be biased since physicians were asked to ex-
clude FGID patients who had improved their GI symptoms and 
the mean severity score in IBS patients was considered as a mod-
erate level at the index visit on the IBS-SSS,13 which was almost 
concordant with the previous findings of validation studies for 
IBS.9,23,24 Lastly, IBS patients were significantly younger in age 
compared with FD patients or control subjects. Younger pop-
ulation might be more educated than older population in Japan. 
In the further studies, socioeconomic status such as an education 
level in each subject should be taken into account. 
In conclusion, the present findings demonstrate that both the 
IBS and FD diagnostic modules on the Japanese version of the 
Rome III diagnostic questionnaire demonstrate good validity and 
reliability. In addition, our findings support the idea that pa-
tient-reported red flag symptoms should not be incorporated into 
the Rome criteria as exclusions. Thus, this Japanese Rome III 
Diagnostic Questionnaire can be used for cross-cultural compar-
isons on functional GI disorders between Japan and other 
countries.
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